WASHINGTON (dpa-AFX) - Arena Pharmaceuticals, Inc. (ARNA) reported a net
loss for the first quarter of $24.3 million or $0.10 per share, compared to a
net loss of $25.3 million or $0.12 per share for the year-ago quarter.
Total revenue for the...
WASHINGTON (dpa-AFX) - Arena Pharmaceuticals Inc. (ARNA) announced favorable
results from a Phase 1 single-ascending dose clinical trial of APD371, a highly
selective and potent agonist of the cannabinoid 2 or CB2 receptor currently in
NEW YORK (TheStreet) -- Arena Pharmaceuticals
shares are up 5.5% to $4.60 in trading on Tuesday after the biopharmaceutical company announced that it received an additional patent for its weight loss treatment, Belviq.The U.S. Patent and...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.